Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia

Ayalew Tefferi, Louis Letendre

Research output: Contribution to journal › Letter › peer-review

64 Scopus citations

Fingerprint

Dive into the research topics of 'Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia'. Together they form a unique fingerprint.